The Union Government has outlined detailed measures for the modernisation, revival, and capacity enhancement of pharmaceutical public sector undertakings (PSUs) in a response to a Lok Sabha query. The press release provides the latest data on the financial performance, approved budget allocations, and steps taken to strengthen operational efficiency across these entities.
Pharmaceutical PSUs, including Indian Drugs and Pharmaceuticals Limited (IDPL), Bengal Chemicals and Pharmaceuticals Limited (BCPL), and other central PSUs, have been the focus of capacity augmentation and modernisation efforts. The government has sanctioned funding to upgrade manufacturing infrastructure, expand production capabilities, and implement remedial measures to address financial and operational challenges.
The release details budget allocations and expenditure for these PSUs over recent years, illustrating the government’s commitment to improving production efficiency and ensuring the availability of essential medicines. Steps taken include upgrading manufacturing facilities, modernising equipment, and streamlining operations to reduce losses and enhance output.
Financial measures also include the settlement of statutory liabilities, restructuring of operational frameworks, and implementing performance monitoring mechanisms. The government continues to oversee and guide the revival strategyfor underperforming units, ensuring that production targets and public health objectives are met.
These initiatives form part of a broader policy framework aimed at strengthening India’s pharmaceutical self-reliance, ensuring essential drug availability, and supporting the overall healthcare ecosystem. The Union Ministry of Chemicals and Fertilisers maintains close coordination with all stakeholders to implement these measures effectively, with detailed reporting and monitoring of outcomes.
